Navigation Links
Device implanted in brain has therapeutic potential for Huntington's disease
Date:6/18/2012

Amsterdam, NL, June 18, 2012 Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects. Now, a group of scientists has successfully treated neurological symptoms in laboratory rats by implanting a device to deliver a genetically engineered neurotrophic factor directly to the brain. They report on their results in the latest issue of Restorative Neurology and Neuroscience.

Researchers used Encapsulated Cell (EC) biodelivery, a platform which can be applied using conventional minimally invasive neurosurgical procedures to target deep brain structures with therapeutic proteins. "Our study adds to the continually increasing body of preclinical and clinical data positioning EC biodelivery as a promising therapeutic delivery method for larger biomolecules. It combines the therapeutic advantages of gene therapy with the well-established safety of a retrievable implant," says lead investigator Jens Torne, NsGene A/S, Ballerup, Denmark.

Investigators made a catheter-like device consisting of a hollow fiber membrane encapsulating a polymeric "scaffold," which provides a surface area to which neurotrophic factor-producing cells can attach. When implanted in the brain, the membrane allows the neurotrophic factor to flow out of the device, as well as allowing nutrients in. Dr. Torne and his colleagues used the neurotrophic factor Meteorin, which plays a role in the development of striatal projection neurons, whose degeneration is a hallmark of Huntington's disease. The scientists engineered ARPE-19 cells to produce Meteorin and used those that produced high levels of Meteorin in their experiment.

The EC biodelivery devices were implanted in the brains of rats followed by injection with quinolinic acid (QA), a potent neurotoxin that causes excitotoxicity, a component of Huntington's disease. They tested three different implant types: devices filled with the high-producing ARPE-19 cells (EC-Meteorin), devices with unmodified ARPE-19 cells (ARPE-19), and devices without cells. Motor dysfunction was tested immediately prior to injection with QA and at two and four weeks after injection.

The research team found that the EC-Meteorin devices significantly protected against QA-induced toxicity. Rats with EC-Meteorin devices manifested near normal neurological performance and significantly reduced loss of brain cells from the QA injection compared to controls. Analysis of the Meteorin-treated brains showed a markedly reduced striatal lesion size. The EC biodelivery devices were found to produce stable or even increasing levels of Meteorin throughout the study. Meteorin diffused readily from the biodelivery device to the striatal tissue.

"Huntington's disease can be diagnosed with high accuracy by genetic testing. Pre-symptomatic administration of a safe therapeutic treatment providing sustained delay or prevention of disease would be of great benefit to patients," says Dr. Torne. "With additional functional and safety data, tests in animals larger than the rat to study distribution, and more accurate disease models to evaluate the therapeutic potential of Meteorin, we anticipate that EC biodelivery can be developed as a platform technology for targeted therapy in patients with Huntington's disease."


'/>"/>
Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert  

Related medicine news :

1. New device warns workers of high levels of airborne metals in minutes rather than weeks
2. Biochip-based device for cell analysis
3. In Rat Study, Eye Device Shows Promise for Restoring Sight
4. Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy
5. Tiny implanted coil improves lung function in patients with severe emphysema
6. This your brain on no self-control
7. Brain-Injury Recovery Varies Widely Among Children
8. Children, brain development and the criminal law
9. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
10. Omega-3 Supplements May Not Aid Aging Brain
11. Mindful Meditation Tied to Healthy Brain Changes: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Device implanted in brain has therapeutic potential for Huntington's disease
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate ... Solutions Series of webinars will start January 31 with a session about understanding ... current health and benefits topics, including employee engagement, pricing transparency, population health and ...
(Date:1/24/2017)... ... 24, 2017 , ... This Saturday, January 28, the BCFA presents more than ... by Alabama Symphony Orchestra musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local ... exhibitors offer a look at Chinese games, crafts & more. Festivities begin at 11:00 ...
(Date:1/24/2017)... ... January 24, 2017 , ... The NewKILO JRP, a three-year project ... co-funded by the European Union (EU), was completed in May 2015. The future definition ... maintained and used in air, which presents some challenges to establishing traceability to the ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
(Date:1/24/2017)... ... ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic study on what ... On Speaking In Tongues” is the creation of published author, Tina Jackson, the editor, ... , “We need to partner with Jesus and be the voice piece to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- Trifecta Clinical , a leading global provider ... Ward to Vice President of Commercial Operations.  Rick ... the promotion of Ericka Atkinson to Vice ... joins Trifecta from Greenphire where he was Vice President ... positions within the healthcare industry throughout his career.  "Rick ...
(Date:1/24/2017)... Results show Gamma Knife spares normal brain tissue ... Elekta (EKTA-B.ST) today announced new data demonstrating ... a higher radiation dose compared to linear accelerator (linac)-based delivery ... complex brain tumors, were published in the Journal ... ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
Breaking Medicine Technology: